Caladrius Biosciences Inc CLBS:NASDAQ

Last Price$0.54NASDAQ Previous Close - Last Trade as of 3:57PM ET 8/12/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$0.50 (7)
Ask (Size)$0.55 (4)
Day Low / HighN/A - N/A
Volume94.9 K
 

View Biotechnology IndustryPeer Comparison as of 08/12/2022

 

Caladrius Biosciences Inc ( NASDAQ )

Price: $0.54
Change: +0.007 (1.34%)
Volume: 94.9 K
3:57PM ET 8/12/2022
 
 

VistaGen Therapeutics Inc ( NASDAQ )

Price: $0.16
Change: -0.02 (10.06%)
Volume: 20.7 M
4:00PM ET 8/12/2022
 
 

T2 Biosystems Inc ( NASDAQ )

Price: $0.19
Change: -0.007 (3.36%)
Volume: 139.3 M
4:00PM ET 8/12/2022
 
 

Marker Therapeutics Inc ( NASDAQ )

Price: $0.39
Change: -0.05 (12.24%)
Volume: 979.4 K
4:00PM ET 8/12/2022
 
 

Aikido Pharma Inc ( NASDAQ )

Price: $6.15
Change: +0.05 (0.82%)
Volume: 31.6 K
3:59PM ET 8/12/2022
 

Read more news Recent News

Caladrius Says Merger Partner Cend to Collaborate With Roche on Pancreatic Cancer Treatment
9:27AM ET 8/10/2022 MT Newswires

Caladrius Biosciences (CLBS) said Wednesday that its prospective merger partner Cend Therapeutics has executed a collaboration agreement with F....

-- Earnings Flash (CLBS) CALADRIUS BIOSCIENCES Posts Q2 Loss $-0.11
4:10PM ET 8/04/2022 MT Newswires

...

Caladrius Biosciences Doses Last Patient in Phase 1b Clinical Study of Diabetic Kidney Disease Drug Candidate
10:00AM ET 8/02/2022 MT Newswires

Caladrius Biosciences (CLBS) said Tuesday it has completed enrollment and dosing in a phase 1b clinical study of CLBS201, the company's investigational...

Caladrius Biosciences to Proceed With Patient Enrollment for CLBS201 Phase 1b Study
10:04AM ET 5/19/2022 MT Newswires

Caladrius Biosciences (CLBS) said Thursday that the independent committee overseeing the phase 1b proof-of-concept study of CLBS201 as treatment for...

Company Profile

Business DescriptionCaladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes XOWNA, CLBS12, CLBS201 and CLBS14. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. View company web site for more details
Address110 Allen Road
Basking Ridge, New Jersey 07920
Phone+1.908.842.0100
Number of Employees25
Recent SEC Filing08/10/2022425
President, Chief Executive Officer & DirectorDavid J. Mazzo
Vice President-Finance & TreasuryJames Nisco
Chief Information Officer, VP-Cybersecurity & ITGregory S. Berkin
Chief Medical OfficerKristen K. Buck

Company Highlights

Price Open$0.53
Previous Close$0.53
52 Week Range$0.40 - 1.34
Market Capitalization$32.5 M
Shares Outstanding60.6 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.41
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-27.17%

Analyst Ratings as of 08/05/2022

Buy
2
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset